Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 15/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 15/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 15/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 14/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19592122 | 0.82 | PDE4A (0.32) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL18159968 | 0.80 | ALDH1A1 (0.40) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL25748391 | 0.78 | PDE4A (0.42) | PDE4APDE4BPDE4DPDE4CADORA3 | |
| SCHEMBL18159969 | 0.78 | ALDH1A1 (0.42) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL18159971 | 0.77 | KDM4E (0.36) | PDE4APDE4BPDE4DPDE4CCTSK | |
| SCHEMBL18159967 | 0.76 | ALDH1A1 (0.36) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL19592157 | 0.74 | MEN1 (0.31) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL19592059 | 0.73 | MEN1 (0.31) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL19592119 | 0.72 | MEN1 (0.33) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL15071353 | 0.72 | GAA (0.37) | PDE4APDE4BPDE4DPDE4CADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815791-B2 | Alkylpyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2017-11-14 | — | — | US | disclosed |
| US-20160304465-A1 | ALKYLPYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304465-A1 | ALKYLPYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | ATP5F1A, ATP5F1D, ATP5ME | PDE4A 184/4885PDE4B 291/4885PDE4D 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.